Navigation Links
New vaccine for brain cancer

For 18 years, Keith Black, M.D., from Cedars-Sinai Medical Center in Los Angeles has been searching for an effective treatment for brain cancer. While his research moves forward, he’s helping patients live longer along the way.// Latest research involves an effective brain tumor vaccine.

Dr. Black says brain tumors try to hide proteins on the tumor cell surface that the immune system could use to recognize the tumor. By hiding these cells, brain tumors become difficult to eradicate. The first step of research strips these “hidden” proteins from tumor cells and then cultures them from a piece of a patient’s tumor that’s removed with surgery. Next, come dendritic cells. Dendritic cells make up a very small percentage of the white blood cells, but they are the most efficient cells for presenting foreign proteins to the immune system. After isolating the dendritic cells, researchers say, they essentially have developed a technique to put these proteins [that the tumor tries to “hide”] directly on these [dendritic cells] and allow these cells to present these back to the proteins to the immune system by giving these cells back under the skin just as a shot, like a vaccine.

Researchers say the killer immune cells then recognize it and divide into millions of powerful T-cells. Now, when they see the tumor with this protein on the surface, they will try to attack it and kill the tumor cell.

It sounds confusing, but it works. By giving this vaccine, patients are surviving longer. Early research suggests, when combined with chemotherapy, the vaccine increases the two-year survival of patients with grade IV glioblastomas -- the deadliest type of brain cancer -- from 5 percent to nearly 40 percent.

However specialist’s newest endeavor is to inject the vaccine directly into the tumor of patients whose cancer has recurred. In the first patient vaccinated this way, the tumor appears to be at least stabilizing. Ultimately, researchers say they hope that they will be able to eliminate the need for surgery altogether by combining this strategy with non-invasive strategies of destroying the tumor and ... just putting these cells right into the tumor to allow the tumor to be eradicated.

Another research found that age matters when predicting length of survival. Hence Younger patients with a grade IV tumor will do much better than a 70-year-old with a grade II tumor, so there’s something related to age that has a huge impact on the survival of these tumors.

Younger patients have more T-cells ... that can be called up to fight these tumors. That accounts for the entire age effect and the survival of these patients. We know that the immune system is really the reason why younger patients do much better with these aggressive tuors.
'"/>




Related medicine news :

1. New hope for cancer victims – will vaccine cure the deadly bug
2. New vaccine helps allergy and asthma patients
3. Man against HIV – new vaccine ready for human trials
4. New vaccine helps allergy and asthma patients
5. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
6. HIV did not arise from polio vaccine
7. Double impact vaccine
8. High Demand for a child vaccine
9. A new vaccine for leukemia
10. Shortage of MMR vaccine
11. Anthrax vaccine produced
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: